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Chemotherapy-induced nausea and vomiting is a common adverse effect in 
cancer patients that not only impacts quality of life, but also treatment outcomes. 
The prevalence of nausea and vomiting is related to several factors, including the 
emetogenicity of the chemotherapy regimen, the dose and rate of administration 
of the chemotherapy agents, various environmental triggers and patient-related 
factors. The pathogenesis involves multiple organ systems, central nervous system, 
gastrointestinal tract and neurotransmitters. Clinical management should include a 
complete assessment of nausea and vomiting to investigate the possible etiology and 
the pharmacologic approach should involve agents that target each of these path-
ways and neurotransmitters. Various national guidelines provide recommendations 
for the prevention and management of CINV and combining these evidence-based 
strategies into clinical practice is crucial l to improve morbidity and quality-of-life 
outcomes among cancer patients.
Keywords: nausea, vomiting, chemotherapy, radiotherapy, risk of emesis, 
management
1. Introduction
Nausea and vomiting (N/V) represents a primary issue in oncology requiring 
effective management for both prevention and treatment. Although in cancer 
patients several causes, such as opioid medications, can induce N/V, it is mainly 
related to antitumoral therapy. Chemotherapy-induced nausea and vomiting 
(CINV) is the most common and intolerable adverse event with negative impact 
on quality of life and treatment’s adherence and efficacy. It is important to notice 
that large literature is available about N/V related to standard chemotherapy and 
little literature about new antitumoral therapies such as tyrosine kinase inhibitors, 
monoclonal antibodies and immunotherapeutic agents, instead. Management of 
N/V in cancer patients should begin with a complete assessment including evalua-
tion of intensity and timing of appearance. To determine whether N/V is related to 
treatment (chemotherapy, radiation) or is independent of cancer treatment should 
be the second step. Various national and international antiemetic guidelines have 
been developed for the prevention of chemotherapy- and radiotherapy-induced 
nausea and emesis. The prevention of CINV is crucial to improve patients’ con-
fidence and compliance to treatments and the clinical management include both 
pharmacologic and nonpharmacologic therapies. This chapter addresses the epide-
miology, clinical features, risk factors, mechanisms, and management of CINV.
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2. Epidemiology
CINV involves about 60–80% of patients with cancer increasing the risk of 
patients’ discomfort and chemotherapy’s discontinuation [1]. The prevention of 
CINV is mainly important in reducing morbidity and total healthcare costs, as well 
as increasing the quality of care in patients receiving emetogenic chemotherapy. 
Patients experiencing CINV may refuse treatment, request or require dose reduc-
tions or seek alternative therapy options. Acute CINV may be prevented in 50% 
to 90% of patients using effective preventive strategies [2]. In a large European 
observational study, 1000 patients who had received guideline antiemetic treatment 
had significantly better CINV control than those who did not receive guideline 
treatment. The complete control rates were 60% versus 51%, respectively; however, 
the overall adherence to guidelines was just 29% [3].
Radiotherapy-induced nausea and vomiting (RINV) is one of the most common 
side effects during radiation, from which about 50% to 80% of the patients under-
going radiotherapy will suffer [4].
3. Clinical presentation
Cancer patients often experience N/V together but not necessarily. It is possible 
to experience nausea without emesis or emesis without nausea. The events of nausea 
and vomiting are generally protecting reflexes to rid intestine and stomach of toxic 
substances.
Nausea is described as a subjective and diffuse feeling of unease and discomfort 
often perceived as an urge to vomit. It can be considered a prodromal phase to the 
act of vomiting. It is characterized by sickness in the stomach, epigastrium and/or 
throat. Vomiting or emesis means the expulsion of stomach contents beyond the 
mouth and is accompanied by shivering and salivation.
The use of single agent cisplatin led to classify CINV into five types: acute, 
delayed, anticipatory, breakthrough and refractory according to the timing of 
appearance and in the absence of effective antiemetic prevention [5]. Acute CINV 
occurs within 24 hours of the chemotherapy administration, while delayed CINV 
occurs after 24 hours and could persist for 2–3 weeks after the administration of 
chemotherapy. Chemotherapeutic agents such as cisplatin, carboplatin, cyclophos-
phamide, anthracyclines are generally related to delayed CINV [6]. Anticipatory 
CINV involves patients who had already experienced N/V and occurs prior to the 
impending administration of chemotherapy triggered by the just thinking of it 
through a sensorial way (sight, smell). The incidence of anticipatory CINV has 
decreased in recent years because of the improved strategies for controlling acute 
and delayed emesis. Breakthrough CINV is vomiting and/or nausea that occurs 
within five days of chemotherapy administration after the use of guideline directed 
prophylactic antiemetic agents. This type of CINV usually requires immediate 
treatment or requires “rescue” with additional antiemetics. Refractory CINV is 
defined as vomiting and/or nausea occurring after chemotherapy in subsequent 
chemotherapy cycles after guideline directed prophylactic antiemetic agents have 
failed in earlier cycles (Table 1).
Patients with CINV should be assessed with a visual analog scale (0 to 10, with 
0 no nausea and 10 maximum nausea). The frequency, severity, time of appearance 
and any associated activities (meals, drugs) should be requested. Recent treatment 
with chemotherapy and/or radiation therapy should then be noted with evalua-
tion of single agent or combination of chemotherapy. The physical examination 
should include a complete assessment of the abdomen in order to identify a possible 
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organic cause of the emesis such as gastritis, bowel obstruction, an inflammatory 
process. A complete neurologic examination should also be performed to determine 
the search focal neurologic signs suggesting intracranial hypertension or meningeal 
carcinosis. Weight loss, appetite, anorexia, and/or cachexia should be evaluated to 
investigate the possible etiology of N/V and to help the differential diagnosis.
4. Risk factors
The occurrence of CINV can depend on several factors. The risk factors for 
CINV are both patient- and treatment-related. The most common patient-related 
risk factors are age, gender, previous motion sickness and/or pregnancy-related 
N/V and previous CINV. Patients younger than 50 years, females, patients with a 
history of previous motion sickness and/or pregnancy-related N/V have a greater 
Clinical presentation and physiopathology
Acute CINV Within 24 hours of initial administration of chemotherapy.
Mainly by 5-HT3 release from the enterochromaffin cells
Delayed CINV After 24 hours of initial administration of chemotherapy to 2–3 weeks.
Mainly by substance P release, disruption of the blood–brain barrier and disruption 
of the gastrointestinal motility.
Anticipatory CINV After a previous cycle of chemotherapy.
Triggered by taste, smell, sight, thoughts of a previous CINV.
Breakthrough 
CINV
Within 5 days of initial administration of chemotherapy.
Refractory CINV After chemotherapy despite prophylactic antiemetic agents
Table 1. 
Clinical presentation and physiopathology of CINV.
High-risk of emesis 
(>90%)
Moderate-risk of emesis 
(30–90%)




Carmustine Procarbazine Bortezomib Bevacizumab
Cisplatin Carboplatin Cetuximab Bleomycin
Cyclophosphamide Cyclophosphamide Docetaxel Busulfan
Dacarbazine Cytosine arabinoside Etoposide Capecitabine
Mechlorethamine Doxorubicin 5-fluorouracil Chlorambucil










Classification of antitumoral therapy according to the risk of emesis.
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risk of experiencing CINV. Instead, a previous history of high alcohol consumption 
is associated with a lower risk of CINV [7–9].
Treatment-related factors and emetogenicity of chemotherapeutic regimens 
are also relevant. Chemotherapeutic agents are related to various risk of emesis 
depending on mechanism of action, dose, route and administration in single or 
combined way. The intrinsic emetogenicity of chemotherapy is the crucial factor to 
guide the choose of antiemetic treatment. In 2004 an expert consensus conference 
proposed a classification of chemotherapeutic agents in four categories according to 
emetogenic potential: high, moderate, low and minimal risk [10]. In the high-risk 
category, more than 90% could experience CINV without an antiemetic prophy-
laxis. In the moderate-risk category the potential experience of CINV involves 
30–90% of patients. In the low- and minimal risk less than 30% and 10% respec-
tively of cancer patients experience CINV (Table 2) [11].
5. Physiopathology
The mechanisms of emesis are not well defined. The physiopathology of CINV 
includes both central nervous and peripheral system pathways and it is different 
in acute, delayed and anticipatory setting. The mechanisms inducing CINV have 
gradually been investigated over the past 60 years. In the 1950s the first hypothesis 
by Wang and Borison was the existence of a central site called ‘vomiting center’ 
located in the medulla processing all the afferent impulses to generate emesis 
[12]. The presence of some neuronal areas located within medulla coordinat-
ing the emetic reflex is now a more realistic hypothesis. All the neuronal cells 
involved in the series of events occurring during CINV have been called ‘central 
pattern generator’ [13]. Three primary components have been found out in the 
physiopathology of CINV: chemoreceptor trigger zone (CTZ), abdominal vagal 
afferents and neurotransmitters. After exposure to chemotherapy, the emetic 
reflex involves two primary sources of afferent input to neuronal areas: abdominal 
vagal afferents and area postrema, a structure located in the caudal end of the 
fourth ventricle [14, 15]. 5-hydroxytryptamine 3 (5-HT3), neurokinin-1 (NK1) and 
cholecystokinin-1 receptors located in the terminal ends of the vagal afferents are 
close to enteroendocrine cell into the gastrointestinal mucosa of the proximal small 
intestine. Chemotherapeutic agents stimulate enteroendocrine cells to release some 
mediators such as 5-hydroxytryptamine, substance P and cholecystokinin which 
bind to the specific receptors on the close vagal fibers. The afferent impulse reaches 
the dorsal brain stem through the nucleus of the solitary tract. Among the various 
receptors, 5-HT3 are considered the most active in acute emesis. In summary, in 
acute CINV chemotherapeutic agents release free radicals stimulating entero-
chromaffin cells in the peripheral gastrointestinal tract with subsequent release of 
serotonin. Serotonin binds 5-HT3 receptors through intestinal vagal afferent nerves 
and nucleus of the solitary tract and reaches the central nervous system. In delayed 
CINV the physiologic way is similar but involves less frequently 5-HT3 and more 
frequently NK1 receptors respectively. In delayed CINV chemotherapeutic agents 
induce the release of substance P from the neuronal cells in the central and periph-
eral nervous system. Substance P binds NK1 receptors in the nucleus of solitary 
tract and led the afferent impulse to central nervous system.
The second pathway potentially involved in the emetic reflex include area 
postrema. In this region of the brain the blood–brain barrier is more permeable so it 
is accessible to afferent impulses in either blood or cerebrospinal fluid. This area has 
commonly been called ‘chemoreceptor trigger zone’. This region has afferent and 
efferent connections with underlying structures, the subnucleous gelatinosus and 
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nucleus of solitary tract, receiving vagal afferent fibers from the gastrointestinal 
mucosa. Metabolites and peptides released under the effect of chemotherapeutic 
agents can also induce emesis binding at this site.
The clinical role of neurotransmitters has been longer investigated in the past 
30 years. The first interest was focused on dopamine, more recently on 5-HT and 
substance P. Dopaminergic antagonists are the first investigated antiemetic agents 
[16]. The 5-HT3 receptor antagonists are currently the single most effective class of 
antiemetics for prevention and treatment of acute CINV. These receptors are located 
both in central sites such as area postrema and nucleus of solitary tract and in 
peripheral sites such as vagal afferents. The blockage of 5-HT3 receptor is the most 
effective mechanism of antiemetic treatment. NK1 receptors are also located both in 
area postrema and nucleus of solitary tract and in the gastrointestinal mucosa. This 
evidence suggests that NK1 receptor antagonists plays a central role in prevention 
and treatment of CINV similar to 5-HT3 receptor antagonists. Endocannabinoids 
have been more recently investigated as relevant neurotransmitters inducing N/V. 
The endogenous cannabinoids are agonistic antiemetic agents. Synthetic cannabi-
noids have been recently evaluated to treat refractory CINV.
Anticipatory CINV occurs as a response to a previous experience of CINV. A 
sensory feeling related to the first administration of chemotherapy led the patient 
to associate that feeling with N/V. Subsequent exposure to that feeling triggers the 
response of N/V. Anticipatory CINV can be effectively avoided with an adequate 
prevention of acute and delayed CINV [7, 17–19].
6. Management
Antiemetic guidelines are published by all the cancer organizations including 
American Society of Clinical Oncology (ASCO), the National Comprehensive 
Cancer Network (NCCN), the European Society of Medical Oncology (ESMO) and 
the Multinational Association of Supportive Care in Cancer (MASCC). There are 
some differences among the guidelines particularly in the choice of the preferred 
5-HT3 receptor antagonist and the use of cannabinoids. The general scheme for 
antiemetic protocols is similar for the various guidelines.
Prevention of CINV is the primary treatment to avoid subsequent episodes of 
CINV and anticipatory CINV. Due to physiopathology of CINV, 5-HT3 and NK1 
receptor antagonists are the main classes of drugs Management include also both 
pharmacologic and nonpharmacologic agents such as steroids, dopamine antago-
nists, benzodiazepines, cannabinoids, antipsychotics. The primary issue is the 
prevention and treatment of moderately and highly emetogenic chemotherapy.
6.1 5-HT3 antagonists
Selective 5-HT3 receptor antagonists have revolutionized the management of 
CINV. They are indicated in preventing and treating N/V induced by chemotherapy 
with moderate and high emetic potential. The 5-HT3 receptor antagonists include 
both first-generation drugs such as ondansetron (Zofran), dolasetron (Anzemet) 
and granisetron (Kytril) with half-life between 3–9 hours and second-generation 
drugs such as palonosetron (Aloxi) with half-life of approximately 40 hours. 
According to their half-life they are used in different indication with more use in 
acute CINV for first-generation drugs and delayed CINV for second-generation 
drugs. The first-generation antiemetic drugs are equivalent in efficacy [20–22] and 
they have few adverse events. The most common adverse events of 5-HT3 receptor 
antagonist include headache, constipation, transient high levels of hepatic enzymes 
Suggestions for Addressing Clinical and Non-Clinical Issues in Palliative Care
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and QT prolongation [23]. The oral and intravenous formulation are therapeuti-
cally equivalent [24]. The first-generation drugs are more active in acute CINV and 
appear little active and modest active in delayed N/V induced by cisplatin and mod-
erately emetogenic chemotherapeutic agents, respectively. The second-generation 
5-HT3 receptor antagonist has a longer half-life and a greater binding affinity for 
the specific receptor. Three randomized prospective trials compared palonosetron 
with a first-generation antiemetic drug in patients receiving moderately and highly 
emetogenic chemotherapy. The noninferiority of palonosetron in term of complete 
response was demonstrated [25–27]. Some international guidelines consider palo-
nosetron the preferred 5-HT3 antagonist for moderate emetogenic chemotherapy 
regimens but there are no prospective trials demonstrating the superiority of 
palonosetron compared to first-generation agents.
6.2 NK1 antagonists
In the past 10 years, antiemetic treatment has greatly advanced with the avail-
ability of NK1 receptor antagonists. The NK1 receptor antagonists are the most 
recent class of antiemetic agents and include aprepitant (emend) fosaprepitant 
(ivemend), rolapitant (varuby) and netupitant (akynzeo). Aprepitant was the first 
approved agent in the class and is formulized as oral drug. In acute CINV the NK1 
receptor antagonists are usually administered in combination with a 5-HT3 recep-
tor antagonists and dexamethasone. 3-days aprepitant can also be administered in 
delayed CINV [28]. Three randomized prospective trials compared the combination 
of ondansetron plus dexamethasone plus aprepitant versus ondansetron and dexa-
methasone in patients receiving highly emetogenic chemotherapy. Aprepitant was 
administered before chemotherapy and continued along with dexamethasone. The 
addition of aprepitant led to an approximate 50% reduction in the risk of emesis or 
need for rescue medications [29–31]. These evidences underline the crucial role of 
aprepitant in the management of CINV induced by highly emetogenic chemother-
apy. A randomized prospective trial investigated the use of aprepitant in moderately 
emetogenic chemotherapy in almost a thousand of patients with breast cancer. A 
significantly higher rate of complete response in the aprepitant group was reported 
[32]. Fosaprepitant is an intravenous NK1 receptor antagonist. In is a water-soluble 
phosphoryl prodrug of aprepitant converted to aprepitant within 30 minutes after 
administration. A randomized double-blind study reported that a single dose of 
fosaprepitant after ondansetron and dexamethasone was noninferior to a standard 
aprepitant 3-days regimen in preventing CINV in more than 2 thousand patients 
receiving cisplatin [33]. This evidence suggests that a single dose of fosaprepitant 
enhances the antiemetic effects provided by conventional 5-HT3 receptor agonists 
and corticosteroid therapy over conventional therapy alone and may provide a 
level of efficacy similar to that of the recommended 3-days aprepitant regimen. 
Rolapitant is a highly selective competitive long-acting NK-1 receptor antagonist 
demonstrating efficacy in randomized phase III trials. A single oral dose of rolapi-
tant was effective in preventing delayed CINV compared with placebo, when each 
was used in combination with a 5-HT3 receptor antagonist plus dexamethasone in 
patients receiving highly or moderately emetogenic chemotherapy [34]. Netupitant 
is formulated with palonosetron in a fixed-dose combination. Complete response 
rates during the acute and delayed CINV were significantly higher with single-dose 
netupitant plus palonosetron than with single-dose palonosetron in highly and 
moderately emetogenic chemotherapy in phase II and III trials [35].
The most common adverse events of NK1 receptor antagonists are fatigue, 
hiccups, dyspepsia and diarrhea. The use of aprepitant requires the evaluation of 
potential drug interaction due to its mechanism of action moderately inhibiting 
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cytochrome CYP3A4. In particularly, aprepitant is related to an increase of plasma 
dexamethasone levels. Dexamethasone dose should be reduced when used in 
combination with aprepitant. Some antitumoral agents are also metabolized by 
CYP3A4 with the risk of increased toxicity when administered in combination with 
aprepitant. Aprepitant is also a weak inducer of the cytochrome CYP450. In patient 
receiving warfarin in combination with aprepitant the international normalized 
ratio (INR) decreases by 15% [36]. Rolapitant is well tolerated and its most com-
mon adverse events include neutropenia and dizziness. It inhibits CYP2D6 and it is 
metabolized by CYP3A4 so CYP3A4 inducers can reduce rolapitant blood levels and 
efficacy. The most common adverse events of netupitant include asthenia, dyspep-
sia, erythema and neutropenia. It is contraindicated in patients with severe renal 
and hepatic failure and it is an inhibitor of CYP3A4 as aprepitant [37–40].
6.3 Steroids
The antiemetic use of corticosteroids dates to the 1980s although the mechanism 
of efficacy is not yet clear. Dexamethasone is the most effective corticosteroid and 
it is widely used in combination with other antiemetic drugs both in acute and 
delayed CINV. In N/V induced by low emetogenic chemotherapy it could also be 
effectively used as single antiemetic agent (Table 3).
6.4 Other antiemetic treatments
A lot of agents including dopamine receptor antagonists, phenothiazines, can-
nabinoids, olanzapine are currently used to treat CINV induced by low emetogenic 
potential. Dopamine receptor antagonists such as metoclopramide and butyrophe-
nones were most commonly used in past years and they could still be administered 
in combination with other antiemetic agents or in low-risk CINV. The efficacy of 
metoclopramide improves with increasing doses. Dopamine antagonists exhibit 
many adverse events and the most serious is represented by extrapyramidal symp-
toms. Dopamine antagonists may be considered when breakthrough CINV occurs. 
Currently breakthrough CINV is managed with an agent from a drug class that was 
not used in the prophylactic regimen. The phenothiazines are rarely administered in 
CINV and mainly in CINV induced by low emetogenic effect or as salvage therapy 
in breakthrough emesis. Antipsychotics such as olanzapine are sometimes pre-
scribed in CINV not responding to conventional antiemetics. Olanzapine antago-
nizes several neurotransmitter receptors involved in the antiemetic reflex and it 
has been reported effective in preventing both and delayed CINV. No robust data 
comparing olanzapine with other antiemetic agents is available [41, 42]. In clinical 
practice olanzapine is often added to the standard three-drugs combination but it 
does not replace any of them. Olanzapine may be considered for the treatment of 
breakthrough and refractory CINV in addition to a change in the prophylactic anti-
emetic regimen. The most common adverse events of olanzapine include fatigue, 
sedation, headache, dry mouth, hyperglycemia, diarrhea.
In CINV with low and moderate emetic potential, synthetic cannabinoids 
have been recently evaluated. The two known cannabinoid receptors are CB1 and 
CB2. Blocking of CB1 and CB2 results in emesis. Cannabinoids act as an agonist 
on the CB1 receptors, resulting in their pharmacologic effect [43]. The use of 
these agents with a lower therapeutic index is not recommended as first-line 
treatment for prevention of CINV and should be reserved for patients refrac-
tory to or intolerant of standard antiemetics. Evidence remains insufficient for a 
recommendation regarding medical marijuana for the prevention of nausea and 
vomiting in patients with cancer who receive chemotherapy or radiation therapy. 
Suggestions for Addressing Clinical and Non-Clinical Issues in Palliative Care
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Two commercial forms of synthetic cannabinoids have been approved by Food 
and Drug Administration (FDA) with CINV indication: nabilone and dronabinol 
in 2005 and 2016, respectively. Studies with dronabinol and nabilone were per-
formed in the 1970s and 1980s, before the approval of 5-HT3 receptor antagonists, 
and often included a placebo arm. Tramer et al. published a meta-analysis on the 
use of cannabinoids for CINV control. The investigators analyzed data from 30 
randomized controlled studies from 1975 to 1997; 16 studies were with nabilone, 
13 with dronabinol, and 1 with intramuscular levonantradol. Of the 30 studies, 
Antiemetic agent Dose
Acute CINV Delayed CINV
Ondansetron 8 mg or 0.15 mg/kg day 1 
(intravenous)
24 mg day 1 for high-risk (oral)
8 mg twice daily day 1 for moderate-
risk (oral)
8 mg twice daily days 2–3 (oral)




Granisetron 1 mg or 0.01 mg/kg day 1 
(intravenous)
2 mg day 1 (oral)
1 mg twice daily days 2–3 (oral)
Palonosetron 0.25 mg day 1 (intravenous)
Aprepitant 125 mg day 1 (oral) 80 mg days 2–3 (oral)
Fosaprepitant 115 mg day 1 (intravenous) 80 mg days 2–3 (oral)
Rolapitant
Netupitant
Dexamethasone 12 mg day 1 (intravenous) with 
aprepitant
12 mg day 1 (oral) with aprepitant
8 mg days 2–4 for high risk (oral) with 
aprepitant
8 mg days 2–3 for moderate-risk (oral) 
with aprepitant
20 mg day 1 for high-risk 
(intravenous) without aprepitant
8 mg day 1 for moderate-risk 
(intravenous) without aprepitant
20 mg day 1 for high-risk (oral) 
without aprepitant
8 mg day 1 for moderate-risk (oral) 
without aprepitant
8 mg twice daily days 2–4 for high risk 
(oral) without aprepitant
8 mg days 2–3 for moderate-risk (oral) 
without aprepitant
Metoclopramide 1–2 mg/kg day 1 (intravenous) 1–2 mg/kg 2 hours after chemotherapy 
(intravenous)
0.5 mg/kg every 6 hours days 2–4 
(oral)
Prochlorperazine 5–10 mg day 1 (intravenous)
5–10 mg day 1 (oral)
5–10 mg every 6 hours (oral)
Dronabinol 5 mg/mq (oral) 5 mg/mq every 2–4 hours (oral)
Nabilone 1–2 mg (oral) 1–2 mg twice daily (oral)
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10 used a placebo as the comparator, and prochlorperazine was prescribed in 
12 trials. Other antiemetic controls included metoclopramide, chlorpromazine, 
thiethylperazine, haloperidol, domperidone, and alizapride. The authors found 
that cannabinoids were more effective with moderately emetogenic chemotherapy 
regimens than all of the active controls, but were not more effective with very 
high or low emetogenic regimens. More side effects were associated with the 
cannabinoid treatment, and patients were more likely to withdraw from therapy 
[44]. A 2015 meta-analysis evaluated the role of cannabinoids in chemotherapy-
induced nausea and vomiting. 51 trials included in the analysis were conducted 
between 1975 and 1991 and none involved comparisons with current antiemetic 
regimens. The authors concluded that cannabis-based medications may be useful 
for treating refractory CINV. However, methodological limitations of the trials 
limit any conclusions [45]. Nabilone and dronabinol are orally active synthetic 
cannabinoid approved for the treatment of CINV in patients who have not experi-
enced adequate response to conventional antiemetic treatments. The restriction is 
related to the side effects spectrum of this agents. Some of these adverse events are 
seen as beneficial to the patient. Events such as a feeling of being high or euphoria 
and drowsiness are seen as potentially beneficial side effects of this agent. Other 
side effects that are not considered beneficial and are more problematic include 
ataxia, anxiety, disorientation, hallucinations, depression, and psychosis. Adverse 
events may persist for a variable and unpredictable period, with adverse psychiat-
ric reactions persisting 48 to 72 hours after the last dose. Orthostatic hypotension 
has been reported. Use of synthetic oral cannabinoids should be limited to the 
management of breakthrough and refractory CONV and they have no place as a 
first-line treatment for CINV.
In the anticipatory CINV benzodiazepines are the treatment of choice due to 
their antianxiety property [17]. Lorazepam or alprazolam are the most used agents 
in the prevention and management of anticipatory emesis in combination with 
standard antiemetic strategies.
Alternative treatments should also be considered particularly for the antici-
patory CINV. Behavioral approaches include hypnosis, muscle relaxion, music 
therapy, acupuncture or acupressure [46]. Evidence remains insufficient for a  
recommendation for or against the use of ginger, acupuncture/acupressure and 
other complementary or alternative therapies for the prevention of nausea and 
vomiting in patients with cancer. The role of ginger in the prevention of CINV 
has been evaluated evaluated in two trials and a meta-analysis. The first trial 
compared powdered ginger plus standard of care versus standard of care alone in 
60 patients treated with anthracycline-based chemotherapy experienced severe 
CINV during previous cycles. Patients in the ginger arm reported less severe 
nausea and fewer vomiting episodes on days 2, 3, and 5. No adverse events were 
attributable to ginger [47]. The second trial compared three doses of ginger versus 
placebo in more than 500 patients receiving a 5-HT3 inhibitor and dexametha-
sone. The two lower doses of ginger produced the largest reductions in nausea 
intensity [48]. A 2013 systematic review evaluated four trials and reported that 
ginger did not have a significant effect on the incidence of acute nausea, acute 
vomiting, or delayed vomiting [49].
The use of acupuncture has been evaluated in 70 patients who were randomly 
assigned to receive acupuncture in cycle 1 and ondansetron in cycle 2, or the 
reverse. All patients also received dexamethasone for 3 days. Complete response 
from 0 to 24 hours was similar with the two treatments, but acupuncture produced 
higher complete response rates from 24 to 120 hours. Constipation and insomnia 
were less common with acupuncture than with ondansetron [50]. Two trials evalu-
ated acupressure wristbands and found no significant benefit against nausea and 
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vomiting when wristbands were added to standard antiemetic treatment among 
patients treated with chemotherapy [51, 52].
6.5 Radiotherapy-induced N/V
Few randomized controlled clinical trials have evaluated the prevention or 
treatment of N/V associated with radiotherapy. As for CINV, RINV is classified 
according to the emetogenic risk of radiation (Table 4).
Patients experiencing high-emetic-risk radiation therapy should be received a 
two-drug combination of a 5-HT3 receptor antagonist and dexamethasone before 
each fraction and on the day after each fraction if radiation therapy is not planned 
for that day. Optimal frequency and duration of prophylactic 5-HT3 receptor 
antagonist therapy and prophylactic dexamethasone therapy for high-emetic-risk 
single-fraction or multiple-fraction radiation are unclear. Previous studies admin-
istered prophylactic 5-HT3 receptor antagonist therapy for durations longer than, 
equal to, and shorter than the duration of radiation therapy. Randomized studies 
comparing these approaches are lacking [53, 54].
Patients receiving moderate-emetic-risk should be treated with a 5-HT3 
receptor antagonist before each fraction, with or without dexamethasone before 
the first five fractions. Optimal frequency and duration of prophylactic 5-HT3 
receptor antagonist therapy for moderate-emetic-risk, single-fraction or multiple-
fraction radiation therapy are unclear. Guidelines recommend prophylaxis before 
each fraction with careful monitoring of patients during radiation therapy sched-
ules that span multiple weeks to detect symptoms experienced during interspersed 
days when radiation therapy and prophylaxis are not administered and to balance 
the benefits and toxicities of prolonged 5-HT3 receptor antagonist therapy. A 
study that involved moderate-emetic-risk radiation therapy demonstrated a ben-
efit for a number of secondary end points by adding prophylactic dexamethasone 
therapy to prophylactic 5-HT3 receptor antagonist therapy before the first five 
fractions [55].
Patients treated with low- and minimal-emetic-risk radiation therapy should 
receive rescue therapy with a 5-HT3 receptor antagonist, dexamethasone, or a 
dopamine receptor antagonist.
Patients who are treated with concurrent radio-chemotherapy should receive 
antiemetic therapy that is appropriate for the emetic risk level of antineoplastic 
agents, unless the risk level of the radiation therapy is higher [56].
One trial evaluated the addition of fosaprepitant to palonosetron and dexameth-
asone among women who received low-emetic-risk pelvic radiation and concurrent 
weekly cisplatin.36 The other trial compared fosaprepitant with olanzapine—each 
given with palonosetron and dexamethasone—among patients with head and neck 
or esophageal cancers who received radiation therapy and concurrent cisplatin and 
fluorouracil.
A systematic review of RINV reported that the clinical trial designs varied con-
siderably in the methodologies, endpoints, and outcome measures employed with 
High-risk of 
emesis (>90%)
Moderate-risk of emesis 
(30–90%)













Classification of radiotherapy according to the risk ok emesis.
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great difficult to conclude definitive recommendations [57]. Most of the patients 
will be suggested to take the antiemetic by the international antiemetic guidelines. 
A MASCC/ESMO consensus systematic review recently evaluated 18 publications. 
The only fully published randomized studies in prevention of RINV were two 
negative studies in acupuncture and green tea, respectively. No data to support 
new recommendations for antiemetic prophylaxis in RINV was available. The 
serotonin receptor antagonists are still the corner stone in antiemetic prophylaxis of 
nausea and vomiting induced by high and moderate emetic risk radiotherapy. The 
emetogenicity of craniospinal radiotherapy was reclassified from low to moderate 
emetic level along with some other minor changes [58]. Further investigations are 
warranted to explore RINV prophylaxis in single fraction, multiple fractions and 
concomitant chemo-radiotherapy.
Although the mechanisms of acupuncture are not completely clear yet, a plenty 
of high-quality clinical trials have been conducted to evaluate the efficacy and 
safety of this therapy and reported that acupuncture could reduce nausea and 
vomiting induce by chemotherapy and radiotherapy with less side effects [50, 59, 
60]. Neural mechanism like stimulating the secretion of endogenous opioid endor-
phin has been proved one of mechanisms of acupuncture therapeutical effect, but 
for RINV relative neural mechanisms have not been found yet [61].
7. Conclusions
CINV represents a common adverse event of chemotherapy with potentially 
significant negative impact on quality of life for patients and their families. 
Prevention and management of CINV is crucial to increase patients’ compliance 
and adherence to antitumoral treatments.
7.1 High-risk of emesis
The combination of a 5-HT3 receptor antagonist, dexamethasone and aprepitant 
before chemotherapy is currently the recommended strategy for chemotherapy 
with high- and moderate-risk of emesis. More robust data is available for cisplatin-
based chemotherapy and anthracycline plus cyclophosphamide regimen, less 
robust data is available for other agents. Approximately 90% of patients receiving 
cisplatin-based chemotherapy and anthracycline plus cyclophosphamide regimen 
develop delayed emesis. These patients should receive a regimen with one of 5-HT3 
receptor antagonists plus 3-days oral aprepitant plus dexamethasone on days 2 to 4 
to avoid delayed emesis.
7.2 Moderate-risk of emesis
For moderate-risk agents different from and anthracycline plus cyclophospha-
mide regimen, a combination of a 5-HT3 receptor antagonist and dexamethasone 
should be administered before chemotherapy. Patients with moderate risk of emesis 
have moderate potential for delayed emesis. These patients should be treated with a 
5-HT3 receptor antagonist or dexamethasone alone on days 2 and 3.
7.3 Low-risk of emesis
For patients receiving chemotherapy with low-risk of emesis, a single dose of 
dexamethasone or a dopaminergic before chemotherapy is currently recommended. 
No routine prevention for delayed emesis is recommended.
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7.4 Minimal-risk of emesis
No routine prevention for acute and delayed CINV is generally indicated for 
chemotherapy with minimal-risk of emesis (Table 5).
Strategies to prevent and manage CINV represents a major challenge. In the 
last 20 years, more effective and well-tolerated antiemetic agents have been intro-
duced in the clinical practice. Selective 5-HT3 receptor antagonist, NK1 antagonist 
receptors and steroids are currently the most effective combination. This antiemetic 
strategy achieved an excellent control of CINV in over 80% of patients with an 
excellent side-effect profile. The further goal should be the management of patients 
with refractory CINV impacting on therapeutic adherence.
Risk of emesis Antiemetic strategy
Acute CINV Delayed CINV
Minimal None None
Low Dexamethasone or 
dopamine antagonist
None
Moderate Anthracycline plus 
cyclophosphamide
5-HT3 receptor antagonist 
plus dexamethasone plus 
aprepitant
Dexamethasone days 2–4 
plus aprepitant days 2–3
Other regimens 5-HT3 receptor antagonist 
plus dexamethasone
5-HT3 receptor antagonist 
or dexamethasone days 2–3
High 5-HT3 receptor antagonist 
plus dexamethasone plus 
aprepitant
Dexamethasone days 2–4 
plus aprepitant days 2–3
Table 5. 
Management of RINV.
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